Literature DB >> 3178453

Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests.

D E Goodkin1, D Hertsgaard, J Seminary.   

Abstract

The need for standardized operational definitions, as well as a more sensitive, easily applied, and reproducible upper extremity functional assessment for following patients in multiple sclerosis clinical trials is evident. Experience with the use of two upper extremity functional assessment instruments--the nine-hole peg test (9HPT) and the box-and-block test (BBT)--is described. The patients, who were followed for six months, experienced subjective change in functional status but failed to show significant change on the pyramidal, cerebellar, or visual functional scores of the Kurtzke Expanded Disability Status Scale (EDSS). The prevalence of upper extremity dysfunction in multiple sclerosis, as measured by the 9HPT and the BBT, is higher than previously appreciated. The 9HPT and BBT are more sensitive in detecting upper extremity functional status change than the EDSS and should prove helpful in following patients in clinical trials.

Entities:  

Mesh:

Year:  1988        PMID: 3178453

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  52 in total

1.  A novel deletion-insertion mutation identified in exon 3 of FXN in two siblings with a severe Friedreich ataxia phenotype.

Authors:  Marguerite V Evans-Galea; Louise A Corben; Justin Hasell; Charles A Galea; Michael C Fahey; Desirée du Sart; Martin B Delatycki
Journal:  Neurogenetics       Date:  2011-08-10       Impact factor: 2.660

2.  The optimal controller delay for myoelectric prostheses.

Authors:  Todd R Farrell; Richard F Weir
Journal:  IEEE Trans Neural Syst Rehabil Eng       Date:  2007-03       Impact factor: 3.802

3.  Sustained-released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of life.

Authors:  Etienne Allart; Anne Benoit; Anne Blanchard-Dauphin; Vincent Tiffreau; André Thevenon; Hélène Zephir; Olivier Outteryck; Arnaud Lacour; Patrick Vermersch
Journal:  J Neurol       Date:  2015-06-05       Impact factor: 4.849

Review 4.  More immunotherapy for multiple sclerosis.

Authors:  R A Hughes; B Sharrack
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-09       Impact factor: 10.154

5.  A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  N Thompson; P Choudhary; R A Hughes; R M Quinlivan
Journal:  J Neurol       Date:  1996-03       Impact factor: 4.849

6.  Psychometric properties of measures of upper limb activity performance in adults with and without spasticity undergoing neurorehabilitation-A systematic review.

Authors:  Shannon Pike; Anne Cusick; Kylie Wales; Lisa Cameron; Lynne Turner-Stokes; Stephen Ashford; Natasha A Lannin
Journal:  PLoS One       Date:  2021-02-11       Impact factor: 3.240

7.  Variations in functioning and disability in multiple sclerosis. A two-year prospective study.

Authors:  Charlotte Ytterberg; Sverker Johansson; Magnus Andersson; Lotta Widén Holmqvist; Lena von Koch
Journal:  J Neurol       Date:  2008-06-17       Impact factor: 4.849

8.  Functional magnetic resonance imaging movers and shakers: does subject-movement cause sampling bias?

Authors:  Glenn R Wylie; Helen Genova; John DeLuca; Nancy Chiaravalloti; James F Sumowski
Journal:  Hum Brain Mapp       Date:  2012-07-30       Impact factor: 5.038

9.  Combining tractography and cortical measures to test system-specific hypotheses in multiple sclerosis.

Authors:  Nikos Gorgoraptis; Claudia A M Wheeler-Kingshott; Thomas M Jenkins; Daniel R Altmann; David H Miller; Alan J Thompson; Olga Ciccarelli
Journal:  Mult Scler       Date:  2010-03-09       Impact factor: 6.312

10.  Recovery after spinal cord relapse in multiple sclerosis is predicted by radial diffusivity.

Authors:  Patrick Freund; Claudia Wheeler-Kingshott; Jonathan Jackson; David Miller; Alan Thompson; Olga Ciccarelli
Journal:  Mult Scler       Date:  2010-08-04       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.